Arthritis, rheumatoid Trials in Magdeburg, Germany
Conditions / Arthritis, rheumatoid / Magdeburg, Germany
Clinical trials for Arthritis, rheumatoid investigate a range of treatment strategies and patient populations.
11 total trials for this combination
Showing top 10 of 11 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01955733 | Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis | TERMINATED | PHASE3 |
| NCT04333147 | Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA) | TERMINATED | PHASE3 |
| NCT03970837 | Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) | TERMINATED | PHASE3 |
| NCT01682512 | Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis | TERMINATED | PHASE3 |
| NCT04134728 | Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors | COMPLETED | PHASE3 |
| NCT00603525 | Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to TNF-α Antagonist Therapy | TERMINATED | PHASE3 |
| NCT02937701 | Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab | COMPLETED | PHASE3 |
| NCT02792699 | Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab | COMPLETED | PHASE3 |
| NCT02137226 | BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis | COMPLETED | PHASE3 |
| NCT03161457 | A Study of JHL1101 Versus MabThera® in Subjects With Severe Rheumatoid Arthritis | TERMINATED | PHASE1 |